Van Hulzen Asset Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-71,970
| Closed | -$3.99M | – | 353 |
|
|
2025
Q3 | $3.99M | Sell |
71,970
-300
| -0.4% | -$17.6K | 0.3% | 70 |
|
|
2025
Q2 | $4.99M | Buy |
72,270
+80
| +0.1% | +$5.44K | 0.42% | 58 |
|
|
2025
Q1 | $5.01M | Sell |
72,190
-67
| -0.1% | -$5.53K | 0.46% | 56 |
|
|
2024
Q4 | $6.22M | Buy |
72,257
+356
| +0.5% | +$38.5K | 0.45% | 58 |
|
|
2024
Q3 | $8.56M | Buy |
71,901
+11
| +0% | +$1.47K | 0.62% | 46 |
|
|
2024
Q2 | $10.3M | Hold |
71,890
| – | – | 0.69% | 47 |
|
|
2024
Q1 | $9.23M | Buy |
71,890
+90
| +0.1% | +$10.7K | 0.61% | 49 |
|
|
2023
Q4 | $7.43M | Hold |
71,800
| – | – | 0.52% | 52 |
|
|
2023
Q3 | $6.53M | Sell |
71,800
-854
| -1% | -$75.2K | 0.5% | 55 |
|
|
2023
Q2 | $5.88M | Sell |
72,654
-546
| -0.7% | -$44.6K | 0.5% | 52 |
|
|
2023
Q1 | $5.83M | Buy |
+73,200
| New | +$5.19M | 0.55% | 50 |
|
|
2022
Q4 | – | Sell |
-73,200
| Closed | -$3.65M | – | 298 |
|
|
2022
Q3 | $3.65M | Hold |
73,200
| – | – | 0.45% | 62 |
|
|
2022
Q2 | $4.08M | Hold |
73,200
| – | – | 0.49% | 55 |
|
|
2022
Q1 | $4.06M | Hold |
73,200
| – | – | 0.43% | 63 |
|
|
2021
Q4 | $4.1M | Sell |
73,200
-2,900
| -4% | -$157K | 0.45% | 62 |
|
|
2021
Q3 | $3.65M | Hold |
76,100
| – | – | 0.54% | 51 |
|
|
2021
Q2 | $3.19M | Hold |
76,100
| – | – | 0.48% | 55 |
|
|
2021
Q1 | $2.56M | Hold |
76,100
| – | – | 0.41% | 62 |
|
|
2020
Q4 | $2.66M | Hold |
76,100
| – | – | 0.4% | 61 |
|
|
2020
Q3 | $2.64M | Hold |
76,100
| – | – | 0.4% | 60 |
|
|
2020
Q2 | $2.49M | Sell |
76,100
-1,000
| -1% | -$31.9K | 0.37% | 54 |
|
|
2020
Q1 | $2.32M | Hold |
77,100
| – | – | 0.5% | 49 |
|
|
2019
Q4 | $2.23M | Hold |
77,100
| – | – | 0.43% | 58 |
|
|
2019
Q3 | $1.99M | Hold |
77,100
| – | – | 0.42% | 51 |
|
|
2019
Q2 | $1.97M | Sell |
77,100
-1,600
| -2% | -$39.5K | 0.43% | 52 |
|
|
2019
Q1 | $2.06M | Hold |
78,700
| – | – | 0.55% | 46 |
|
|
2018
Q4 | $1.81M | Hold |
78,700
| – | – | 0.53% | 51 |
|
|
2018
Q3 | $1.85M | Buy |
78,700
+1,600
| +2% | +$39K | 0.49% | 54 |
|
|
2018
Q2 | $1.78M | Hold |
77,100
| – | – | 0.53% | 54 |
|
|
2018
Q1 | $1.9M | Hold |
77,100
| – | – | 0.58% | 56 |
|
|
2017
Q4 | $2.07M | Buy |
77,100
+4,100
| +6% | +$104K | 0.63% | 53 |
|
|
2017
Q3 | $1.76M | Hold |
73,000
| – | – | 0.59% | 53 |
|
|
2017
Q2 | $1.56M | Buy |
+73,000
| New | +$1.47M | 0.62% | 50 |
|
Other funds holding NVO
F
Van Hulzen Asset Management's NVO Position: Q4 2025 in Review
Van Hulzen Asset Management sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 71,970 shares — an estimated $3.99M sold.
Van Hulzen Asset Management first reported a position in NVO in Q2 2017 and held it in 33 quarters. The position peaked at $10.3M in Q2 2024. 1,413 funds tracked by Wall St. Rank hold NVO as of Q4 2025.
- Van Hulzen Asset Management reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
- Van Hulzen Asset Management sold 71,970 Novo Nordisk shares in Q4 2025, an estimated $3.99M.
- Van Hulzen Asset Management first reported a position in Novo Nordisk in Q2 2017 and held it in 33 quarters.
- Van Hulzen Asset Management's Novo Nordisk position peaked at $10.3M in Q2 2024.
- 1,413 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.
Based on Van Hulzen Asset Management's 13F filing for Q4 2025, filed 6 Feb 2026.